Aggressive Leukemic Non-Nodal Mantle Cell Lymphoma With P53 Gene Rearrangement/Mutation is Highly Responsive to Rituximab/Ibrutinib Combination Therapy

Clin Lymphoma Myeloma Leuk. 2019 Feb;19(2):e93-e97. doi: 10.1016/j.clml.2018.11.007. Epub 2018 Nov 13.
No abstract available

Keywords: Case report; Leukemic; Mantle cell lymphoma; Non-nodal; P53 gene mutation.

Publication types

  • Case Reports

MeSH terms

  • Adenine / analogs & derivatives
  • Antineoplastic Agents, Immunological / pharmacology
  • Antineoplastic Agents, Immunological / therapeutic use*
  • Gene Rearrangement / genetics*
  • Humans
  • Lymphoma, Mantle-Cell / drug therapy*
  • Lymphoma, Mantle-Cell / genetics*
  • Lymphoma, Mantle-Cell / pathology
  • Male
  • Middle Aged
  • Mutation
  • Piperidines
  • Pyrazoles / pharmacology
  • Pyrazoles / therapeutic use*
  • Pyrimidines / pharmacology
  • Pyrimidines / therapeutic use*
  • Rituximab / pharmacology
  • Rituximab / therapeutic use*
  • Tumor Suppressor Protein p53 / genetics*

Substances

  • Antineoplastic Agents, Immunological
  • Piperidines
  • Pyrazoles
  • Pyrimidines
  • Tumor Suppressor Protein p53
  • ibrutinib
  • Rituximab
  • Adenine